Reference is made to the stock exchange announcement published by BerGenBio ASA
(the "Company") on 30 May 2023, regarding the commencement of the subscription
period in the rights issue (the "Rights Issue") and the receipt of subscription
rights in the Rights Issue by certain primary insiders and certain close
associates of primary insiders of the Company.

Today, the Company has been informed that Martin Olin, CEO of the Company, on 5
June 2023, exercised 1,046,125 subscription rights in the Rights Issue,
entitling Martin Olin to be allocated 1,046,125 offer shares in the Rights Issue
at a price per offer share of NOK 0.10, subject to the Rights Issue being
completed.

Please see further details about the transactions in the attached forms.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.